AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21786524 — intervention group
Group type: COMPARATOR
Intervention: 150 mg pregabalin
Number of subjects: 74
Study 21786524 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg midazolam (placebo)
Number of subjects: 74
Study 19208256 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Random Fields (CRFs)
Number of subjects: 0
Study 19208256 — intervention group
Group type: COMPARATOR
Intervention: Support Vector Machines
Number of subjects: 0
Study 17924845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II)
Number of subjects: 54
Study 17924845 — intervention group
Group type: COMPARATOR
Intervention: Immediate curative therapy without CAB (Group I)
Number of subjects: 54
Study 15083959 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily OL-HDF (2 to 2.5 hours, six times per week)
Number of subjects: 24
Study 15083959 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly OL-HDF (4 to 5 hours) - Control group
Number of subjects: 24
Study 11219483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 5-day
Number of subjects: 527
Study 11219483 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 7-day
Number of subjects: 527
Study 11219483 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 10-day
Number of subjects: 527
Study 9831631 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP polymorphisms (MTP/-400 (A->t) and MTP/-164 (T->c))
Number of subjects: 1350
Study 9831631 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 1350
Study 9831631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MI
Number of subjects: 1350
Study 7926056 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult screening without dietary restrictions
Number of subjects: 153
Study 7926056 — intervention group
Group type: COMPARATOR
Intervention: Haemoccult screening with dietary restrictions
Number of subjects: 153
Study 1736162 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/d)
Number of subjects: 52
Study 1736162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 410205 — intervention group
Group type: EXPERIMENTAL
Intervention: haptoglobin type hp 1-1
Number of subjects: 167
Study 410205 — intervention group
Group type: COMPARATOR
Intervention: haptoglobin types hp 2-1 and hp 2-2
Number of subjects: 167
Study 31376516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon of deer liquid (TD) supplementation
Number of subjects: 16
Study 31376516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24861696 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW/QW
Number of subjects: 748
Study 24861696 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg QW/QW
Number of subjects: 748
Study 24861696 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 748
Study 24169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (3.5 mL of autologous platelets buffered with 8.4% sodium bicarbonate)
Number of subjects: 60
Study 24169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) injection (1 mL triamcinolone, 40 mg/mL + 2 mL lidocaine, 10 mg/mL)
Number of subjects: 60
Study 24169302 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (3 mL saline, 0.9%)
Number of subjects: 60
Study 20880292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/kg)
Number of subjects: 720
Study 20880292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (high level)
Number of subjects: 720
Study 20880292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and vaccination routine interaction
Number of subjects: 720
Study 19164620 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL) and Macintosh laryngoscope
Number of subjects: 41
Study 19164620 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 41
Study 16717305 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous remifentanil infusion
Number of subjects: 30
Study 16717305 — intervention group
Group type: COMPARATOR
Intervention: Intermittent morphine alone
Number of subjects: 30
Study 16935471 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 3% VC-IP cream for 3 weeks
Number of subjects: 0
Study 12711233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet analysis of EMG signals from two different shoulder muscles
Number of subjects: 0
Study 12711233 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intermittency measure
Number of subjects: 0
Study 10598693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (COSOPT) twice daily
Number of subjects: 253
Study 10598693 — intervention group
Group type: COMPARATOR
Intervention: Timolol (TIMOPTIC) twice daily
Number of subjects: 253
Study 10598693 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide (TRUSOPT) three times daily
Number of subjects: 253
Study 10598693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (COSOPT)
Number of subjects: 253
Study 10598693 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide (TRUSOPT)
Number of subjects: 253
Study 10598693 — intervention group
Group type: COMPARATOR
Intervention: Timolol (TIMOPTIC)
Number of subjects: 253
Study 8524486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (mean resting blood pressure > 107 mmHg)
Number of subjects: 74
Study 8524486 — intervention group
Group type: COMPARATOR
Intervention: Normotensive patients (mean resting blood pressure ≤ 107 mmHg)
Number of subjects: 74
Study 2287795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0
Study 2287795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7000061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 30
Study 7000061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31586510 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning arm (sugar-sweetened beverages displayed a front-of-package health warning)
Number of subjects: 400
Study 31586510 — intervention group
Group type: COMPARATOR
Intervention: Control arm (sugar-sweetened beverages displayed a control label)
Number of subjects: 400
Study 29255098 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules (24 × 10^9 colony-forming units of lactobacilli and bifidobacteria)
Number of subjects: 1009
Study 29255098 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum
Number of subjects: 1009
Study 29255098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol gum (5 pieces daily)
Number of subjects: 1009
Study 29255098 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum (15% xylitol; 5 pieces daily)
Number of subjects: 1009
Study 25854191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalt combined with Mepilex dressing
Number of subjects: 60
Study 25854191 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze dressing
Number of subjects: 60
Study 23297867 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Concerta®), up-titrated over 2 weeks to a maximum dose of 54 mg daily for 20 weeks, given under daily supervision.
Number of subjects: 79
Study 23297867 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered under the same conditions as methylphenidate.
Number of subjects: 79
Study 21894705 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Neimadian(Extra)
Number of subjects: 120
Study 21894705 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with Sufentanil
Number of subjects: 120
Study 19850248 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose reteplase + abciximab
Number of subjects: 2452
Study 19850248 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab alone
Number of subjects: 2452
Study 19850248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (abciximab in the cath lab)
Number of subjects: 2452
Study 17234657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium yeast preparation (100 microg daily, n=99)
Number of subjects: 197
Study 17234657 — intervention group
Group type: COMPARATOR
Intervention: Placebo (yeast only, n=98)
Number of subjects: 197
Study 15293890 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate days (n = 17)
Number of subjects: 29
Study 15293890 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) and veralipride (100 mg/day) on alternate months (n = 12)
Number of subjects: 29
Study 15293890 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene and veralipride (both protocols)
Number of subjects: 29
Study 11380743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led interdisciplinary intervention program for delirium
Number of subjects: 120
Study 11380743 — intervention group
Group type: COMPARATOR
Intervention: Usual care/nonintervention cohort
Number of subjects: 120
Study 9403933 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dinitrochlorobenzene (DNCB) therapy
Number of subjects: 8
Study 9403933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DNCB therapy)
Number of subjects: 8
Study 8389106 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-679 500 mg
Number of subjects: 9
Study 8389106 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-679 125 mg
Number of subjects: 9
Study 8389106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3549028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.05 mg X kg‐1
Number of subjects: 60
Study 3549028 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 31551217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment
Number of subjects: 74
Study 31551217 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel treatment (Control)
Number of subjects: 74
Study 28221247 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention using the web-application young.constant-care.com (YCC) on a monthly basis and during flare-ups, with annual outpatient visits.
Number of subjects: 53
Study 28221247 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Number of subjects: 53
Study 28221247 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard visits every third month.
Number of subjects: 53
Study 26395762 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 120
Study 26395762 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 120
Study 23771826 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 27
Study 23771826 — intervention group
Group type: COMPARATOR
Intervention: Placebo Kinesio taping
Number of subjects: 27
Study 23771826 — intervention group
Group type: COMPARATOR
Intervention: Without taping
Number of subjects: 27
Study 21811172 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 92
Study 21811172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19622902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 933
Study 16677182 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral functional training plus high-calorie and high-protein diet
Number of subjects: 14
Study 16677182 — intervention group
Group type: COMPARATOR
Intervention: High-calorie and high-protein diet (supplement group)
Number of subjects: 14
Study 15290410 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine group (n = 10) received 14 mg of tetracaine and 0.2 mg of epinephrine
Number of subjects: 20
Study 15290410 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) received 14 mg of tetracaine
Number of subjects: 20
Study 12175355 — intervention group
Group type: EXPERIMENTAL
Intervention: New information leaflet
Number of subjects: 100
Study 12175355 — intervention group
Group type: COMPARATOR
Intervention: Old information leaflet
Number of subjects: 100
Study 9666867 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (0.25 IU/kg/week)
Number of subjects: 20
Study 9666867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first 6 months) then switched to GH therapy
Number of subjects: 20
Study 8120554 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) starting on day 6 with 5-FU/LCV
Number of subjects: 37
Study 8120554 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) starting on day 1 with 5-FU/LCV
Number of subjects: 37
Study 8120554 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 37
Study 2803050 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 8 g
Number of subjects: 12
Study 2803050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 53553 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 with hypertonic urea
Number of subjects: 27
Study 53553 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 with hypertonic glucose
Number of subjects: 27
Study 53553 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 alone
Number of subjects: 27
Study 31017470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin 3
Number of subjects: 5154
Study 31017470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin 3 measured in the chronic phase (one month)
Number of subjects: 5154
Study 31265972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 172
Study 29016646 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 71
Study 29016646 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 71
Study 26180352 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion-distraction manipulation therapy combined with conservative physical therapy
Number of subjects: 30
Study 26180352 — intervention group
Group type: COMPARATOR
Intervention: Conservative physical therapy
Number of subjects: 30
Study 23520169 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 200
Study 23520169 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 200
Study 21468387 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous osteotomy
Number of subjects: 20
Study 21468387 — intervention group
Group type: COMPARATOR
Intervention: Endonasal osteotomy
Number of subjects: 20
Study 19361723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) brackets
Number of subjects: 26
Study 19361723 — intervention group
Group type: COMPARATOR
Intervention: Elastomeric (E) brackets
Number of subjects: 26
Study 19361723 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP-driven bioluminescence
Number of subjects: 26
Study 16736519 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline OPG:RANKL ratio
Number of subjects: 92
Study 16736519 — intervention group
Group type: EXPERIMENTAL
Intervention: First-year time-averaged erythrocyte sedimentation rate (tESR)
Number of subjects: 92
Study 16736519 — intervention group
Group type: EXPERIMENTAL
Intervention: High tESR and low OPG:RANKL ratio
Number of subjects: 92
Study 16736519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tESR and high OPG:RANKL ratio
Number of subjects: 92
Study 15047788 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps program
Number of subjects: 0
Study 10754625 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream and plastic occlusive dressing
Number of subjects: 202
Study 10754625 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream and plastic occlusive dressing
Number of subjects: 202
Study 10754625 — intervention group
Group type: COMPARATOR
Intervention: Nothing on the skin (control)
Number of subjects: 202
Study 10754625 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic occlusive dressing
Number of subjects: 202
Study 10754625 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream and plastic occlusive dressing for 60 min
Number of subjects: 202
Study 8970892 — intervention group
Group type: COMPARATOR
Intervention: Single oral phosphate dose (1500 mg in water)
Number of subjects: 10
Study 8970892 — intervention group
Group type: COMPARATOR
Intervention: Three consecutive oral phosphate doses (3 x 500 mg in water)
Number of subjects: 10
Study 1728934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg gemfibrozil (two 300 mg capsules twice daily)
Number of subjects: 322
Study 1728934 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil (one 600 mg tablet twice daily)
Number of subjects: 322
Study 1728934 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg gemfibrozil (two 450 mg tablets in the evening)
Number of subjects: 322
Study 1728934 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (all formulations)
Number of subjects: 322
Study 1728934 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg gemfibrozil
Number of subjects: 322
Study 6365235 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxycillin (3 g) and clavulanate (250 mg)
Number of subjects: 121
Study 6365235 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular procaine penicillin (2.4 MU)
Number of subjects: 121
Study 29987586 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model, delivered in eight sessions.
Number of subjects: 480
Study 29987586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 480
Study 29987586 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model.
Number of subjects: 480
Study 28658491 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2032
Study 28658491 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 2032
Study 26717223 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-mg prasugrel loading dose
Number of subjects: 50
Study 26717223 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel standard dose
Number of subjects: 50
Study 23109650 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure management programme (HFMP)
Number of subjects: 160
Study 23109650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HFMP)
Number of subjects: 160
Study 21800004 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g/day n3‐PUFA
Number of subjects: 36
Study 21800004 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day n3‐PUFA
Number of subjects: 36
Study 21800004 — intervention group
Group type: EXPERIMENTAL
Intervention: n3‐PUFA
Number of subjects: 36
Study 21800004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19501883 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin plus tenoxicam 20 mg
Number of subjects: 57
Study 19501883 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin 4 mg
Number of subjects: 57
Study 16716975 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 months interval between surveillance colonoscopies (group A)
Number of subjects: 944
Study 16716975 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 months interval between surveillance colonoscopies (group B)
Number of subjects: 944
Study 16716975 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months interval between surveillance colonoscopies (group C)
Number of subjects: 944
Study 16716975 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months interval between surveillance colonoscopies (group D)
Number of subjects: 944
Study 16716975 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months interval between surveillance colonoscopies (group E)
Number of subjects: 944
Study 16716975 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 months interval between surveillance colonoscopies (group F)
Number of subjects: 944
Study 15033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HT)
Number of subjects: 2550
Study 15033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia (HCOL)
Number of subjects: 2550
Study 15033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2550
Study 15033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco dependency
Number of subjects: 2550
Study 15033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2550
Study 15033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of CVRF
Number of subjects: 2550
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 0.35 mg/kg twice daily
Number of subjects: 53
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 1.5 mg/kg twice daily
Number of subjects: 53
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 4 mg/kg twice daily
Number of subjects: 53
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 3 mg/kg once daily
Number of subjects: 53
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg (tablets) for adolescents
Number of subjects: 53
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (all doses)
Number of subjects: 53
Study 10681323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 3 mg/kg/day
Number of subjects: 53
Study 9316958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (1 mg/kg)
Number of subjects: 164
Study 9316958 — intervention group
Group type: COMPARATOR
Intervention: Caudal analgesia (1 ml/kg 0.20% bupivacaine with 1/200,000 epinephrine)
Number of subjects: 164
Study 1546860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 31
Study 1546860 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 31